Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Oruka Therapeutics, Inc.

Contributing Author

Recent Articles by Oruka Therapeutics, Inc.

Aug-24
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer ORKA -5.13% GlobeNewswire
Aug-10
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update ORKA +6.40% GlobeNewswire
May-28
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference ORKA GlobeNewswire
May-13
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update ORKA GlobeNewswire
Apr-28
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering ORKA ORKA -7.96% GlobeNewswire
Apr-27
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering ORKA +10.66% GlobeNewswire
Apr-27
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis ORKA +10.66% GlobeNewswire
Apr-26
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 ORKA GlobeNewswire
Mar-12
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ORKA -7.03% ORKA +25.04% GlobeNewswire
Feb-09
Oruka Therapeutics to Participate in Multiple Upcoming Conferences ORKA GlobeNewswire
Jan-12
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 ORKA +10.16% GlobeNewswire
Jan-06
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference ORKA GlobeNewswire
Dec-11
Oruka Therapeutics Announces New Board Member and Board Transition ORKA GlobeNewswire
Nov-12
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update ORKA ORKA -6.78% GlobeNewswire
Oct-29
Oruka Therapeutics to Present at Multiple November Investor Conferences ORKA GlobeNewswire
Sep-17
Oruka Therapeutics Announces $180 Million Private Placement ORKA +8.79% GlobeNewswire
Sep-17
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 ORKA +8.79% GlobeNewswire
Aug-11
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ORKA ORKA +6.90% GlobeNewswire
Jul-21
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September ORKA -5.30% GlobeNewswire
Jul-01
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer ORKA +5.26% ORKA +6.86% GlobeNewswire
May-21
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference ORKA GlobeNewswire
May-20
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody ORKA GlobeNewswire
May-14
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ORKA GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)